Candidate targets for new antivirulence drugs: Selected cases of bacterial adhesion and biofilm formation

Future Microbiology

Volumn 2, Issue 6, 2007, Pages 643-653

  Klemm, Per ^a   Hancock, Viktoria ^a   Kvist, Malin ^a   Schembri, Mark A ^b  

^a TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Antimicrobial agents; Bacterial adhesion; Bacterial infections; Biofilms; Drug design; Fimbriae; Iron; Quorum sensing; Ract infections; Urinary

Indexed keywords

ADHESIN; AMOXICILLIN; ANTIINFECTIVE AGENT; CARBENICILLIN; CEFALOTIN; CEFAMANDOLE; EDETIC ACID; ETHYLENEDIAMINE DERIVATIVE; ETHYLENEDIAMINEDISUCCINIC ACID; GENTAMICIN; MINOCYCLINE; NEW DRUG; NITRIC OXIDE; OVOTRANSFERRIN; PROTAMINE SULFATE; TOBRAMYCIN; TRICLOSAN; UNCLASSIFIED DRUG; VANCOMYCIN; VIRULENCE FACTOR;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM ADHERENCE; BIOFILM; CATHETER INFECTION; COMBINATION CHEMOTHERAPY; DEVICE INFECTION; DRUG TARGETING; HYDRODYNAMICS; MATERIAL COATING; MONOTHERAPY; NONHUMAN; PHENOTYPIC VARIATION; PRIORITY JOURNAL; QUORUM SENSING; REVIEW;

ADHESINS, BACTERIAL; ANTI-BACTERIAL AGENTS; BACTERIAL ADHESION; BACTERIAL INFECTIONS; BIOFILMS;

BACTERIA (MICROORGANISMS);

EID: 37549024190     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460913.2.6.643     Document Type: Review

References (73)

1. Costerton JW, Stewart PS, Greenberg EP: Bacterial biofilms: a common cause of persistent infections. Science 284, 1318-1322 (1999).
2. Roberts JA, Marklund BI, Ilver D et al.: The Gal(α1-4)Gal-specific tip adhesin of Escherichia coli P-fimbriae is needed for pyelonephritis to occur in the normal urinary tract. Proc. Natl Acad. Sci. USA 91, 11889-11893 (1994).
3. Wu XR, Sun TT, Medina JJ: In vitro binding of type 1-fimbriated Escherichia coli to uroplakins Ia and Ib: relation to urinary tract infections. Proc. Natl Acad. Sci. USA 93, 9630-9635 (1996).
4. Mulvey MA, Lopez-Boado YS, Wilson CL et al.: Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli. Science 282, 1494-1497 (1998).
5. Connell H, Agace W, Klemm P, Schembri M, Marild S, Svanborg C: Type 1 fimbrial expression enhances Escherichia coli virulence for the urinary tract. Proc. Natl Acad. Sci. USA 93, 9827-9832 (1996).
6. Klemm P, Hancock V, Schembri MA: Mellowing out: adaptation to commensalism by Escherichia coli asymptomatic bacteriuria strain 83972. Infect. Immun. 75, 3688-3695 (2007).
7. Klemm P, Roos V, Ulett GC, Svanborg C, Schembri MA: Molecular characterization of the Escherichia coli asymptomatic bacteriuria strain 83972: the taming of a pathogen. Infect. Immun. 74, 781-785 (2006).
8. Roos V, Schembri MA, Ulett GC, Klemm P: Asymptomatic bacteriuria Escherichia coli strain 83972 carries mutations in the foc locus and is unable to express F1C fimbriae. Microbiology 152, 1799-1806 (2006).
9. Pizarro-Cerdá J, Cossart P: Bacterial adhesion and entry into host cells. Cell 124, 715-727 (2006).
10. Foster TJ: The Staphylococcus aureus 'superbug'. J. Clin. Invest. 114, 1693-1696 (2004).
11. Odenbreit S: Adherence properties of Helicobacter pylori: impact on pathogenesis and adaptation to the host. Int. J. Med. Microbiol. 295, 317-324 (2005).
12. Gerlach GF, Clegg S, Allen BL: Identification and characterization of the genes encoding the type 3 and type 1 fimbrial adhesins of Klebsiella pneumoniae. J. Bacteriol. 171, 1262-1270 (1989).
13. Rocha SPD, Pelayo JS, Elias WP: Fimbriae of uropathogenic Proteus mirabilis. FEMS Immunol. Med. Microbiol. 51, 1-7 (2007).
14. Ledeboer NA, Frye JG, McClelland M, Jones BD: Salmonella enterica serovar Typhimurium requires the Lpf, Pef, and Tafi fimbriae for biofilm formation on HEp-2 tissue culture cells and chicken intestinal epithelium. Infect. Immun. 74, 3156-3169 (2006).
15. Klemm P, Schembri MA: Bacterial adhesins: function and structure. Int. J. Med. Microbiol. 290, 27-35 (2000).
16. Jones CH, Pinkner JS, Roth R et al.: FimH adhesin of type 1 pili is assembled into a fibrillar tip structure in the Enterobacteriaceae. Proc. Natl Acad. Sci. USA 92, 2081-2085 (1995).
17. Kuehn MJ, Jacob-Dubuisson F, Dodson K, Slonim L, Striker R, Hultgren SJ: Genetic, biochemical, and structural studies of biogenesis of adhesive pili in bacteria. Methods Enzymol. 236, 282-306 (1994).
18. Klemm P: FimC, a chaperone-like periplasmic protein of Escherichia coli involved in biogenesis of type 1 fimbriae. Res. Microbiol. 143, 831-838 (1992).
19. Klemm P. Christiansen G: The fimD gene required for cell surface localization of Escherichia coli type 1 fimbriae. Mol. Gen. Genet. 220, 334-339 (1990).
20. Jones CH, Pinkner JS, Nicholes AV, Slonim LN, Abraham SN, Hultgren SJ: FimC is a periplasmic PapD-like chaperone that directs assembly of type 1 pili in bacteria. Proc. Natl Acad. Sci. USA 90, 8397-8401 (1993).
21. Choudhury D, Thompson A, Stojanoff V et al.: X-ray structure of the FimC-FimH chaperone-adhesin complex from uropathogenic Escherichia coli. Science 285, 1061-1066 (1999).
22. Hultgren SJ, Jones CH, Normark S: Bacterial adhesins and their assembly. In: Escherichia coli and Salmonella: Cellular and Molecular Biology. Neidhardt FC, Curtiss R III, Ingraha, JL et al. (Eds), ASM Press, Washington DC, USA 2730-2756 (1996).
23. Lewis K: Riddle of biofilm resistance. Antimicrob. Agents Chemother. 45, 999-1007 (2001).
24. Darouiche RO: Treatment of infections associated with surgical implants. N. Engl. J. Med. 350, 1422-1429 (2004).
25. Anderl JN, Franklin MJ, Stewart PS: Role of antibiotic penetration limitation in Klebsiella pneumoniae biofilm resistance to ampicillin and ciprofloxacin. Antimicrob. Agents Chemother. 44, 1818-1824 (2000).
26. Schembri MA, Klemm P: Biofilm formation in a hydrodynamic environment by novel FimH variants and ramifications for virulence. Infect. Immun. 69, 1322-1328 (2001).
27. Pratt LA, Kolter R: Genetic analysis of Escherichia coli biofilm formation: roles of flagella, motility, chemotaxis and type I pili. Mol. Microbiol. 30, 285-293 (1998).
28. Henderson IR, Owen P, Nataro JP: Molecular switches - the ON and OFF of bacterial phase variation. Mol. Microbiol. 33, 919-932 (1999).
29. Whitchurch C, Tolker-Nielsen T, Ragas P, Mattick J: Extracellular DNA required for bacterial biofilm formation. Science 295, 1487 (2002).
30. Pinkner JS, Remaut H, Buelens F et al.: Rationally designed small compounds inhibit pilus biogenesis in uropathogenic bacteria. Proc. Natl Acad. Sci. USA 103, 17897-17902 (2006).
31. Aberg V, Almqvist F: Pilicides-small molecules targeting bacterial virulence. Org. Biomol. Chem. 5, 1827-1834 (2007).
32. Min G, Stolz M, Zhou G et al.: Localization of uroplakin Ia, the urothelial receptor for bacterial adhesin FimH, on the six inner domains of the 16 nm urothelial plaque particle. J. Mol. Biol. 317, 697-706 (2002).
33. Zhou G, Mo WJ, Sebbel P et al.: Uroplakin Ia is the urothelial receptor for uropathogenic Escherichia coli: evidence from in vitro FimH binding. J. Cell. Sci. 114, 4095-4103 (2001).
34. Bouckaert J, Berglund J, Schembri M et al.: Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin. Mol. Microbiol. 55, 441-455 (2005).
35. Firon N, Ashkenazi S, Mirelman D, Ofek I, Sharon N: Aromatic alpha-glycosides of mannose are powerful inhibitors of the adherence of type 1 fimbriated Escherichia coli to yeast and intestinal epithelial cells. Infect. Immun. 55, 472-476 (1987).
36. Nagahori N, Lee RT, Nishimura S, Page D, Roy R, Lee YC: Inhibition of adhesion of type 1 fimbriated Escherichia coli to highly mannosylated ligands. Chembiochem. 3, 836-844 (2002).
37. Langermann S, Palaszynski S, Barnhart M et al.: Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination. Science 276, 607-611 (1997).
38. Langermann S, Ballou WR: Development of a recombinant FimCH vaccine for urinary tract infections. Adv. Exp. Med. Biol. 539, 635-648 (2003).
39. Hancock V, Klemm P: Global gene expression profiling of asymptomatic bacteriuria Echerichia coli during biofilm growth in human urine. Infect. Immun. 75, 966-976 (2007).
40. Hancock V, Ferrièes L, Klemm P: The ferric yersiniabactin uptake receptor FyuA is required for efficient biofilm formation by urinary tract infectious Escherichia coli in. human urine. Microbiology (2007) (In press).
41. Banin E, Vasil ML, Greenberg EP: Iron and Pseudomonas aeruginosa biofilm formation. Proc. Natl Acad. Sci. USA 102, 11076-11081 (2005).
42. Kaneko Y, Thoendel M, Olakanmi O, Britigan BE, Singh PK: The transition metal gallium disrupts Pseudomonas aeruginosa iron metabolism and has antimicrobial and antibiofilm activity. J. Clin. Invest. 117, 877-888 (2007).
43. Banin E, Brady KM, Greenberg EP: Chelator induced dispersal and killing of Pseudomonas aeruginosa cells in a biofilm. Appl. Environ. Microbiol. 72, 2064-2069 (2006):
44. Musk DJ, Banko DA, Hergemother PJ: Iron salts perturb biofilm formation and disrupt existing biofilms of Pseudomonas aeruginosa. Chem. Biol. 12, 789-796 (2005).
45. Harrison JJ, Ceri H, Roper NJ, Badry EA. Sproule KM, Turner RJ: Persister cells mediate tolerance to metal oxyanions in Escherichia coli. Microbiology 151, 3181-3195 (2005).
46. Teitzel GM, Geddie A, De Long SK, Kirisits MJ, Whiteley M, Parsek MR: Survival and growth in the presence of elevated copper: transcriptional profiling of copper-stressed Pseudomonas aeruginosa. J. Bacteriol. 188, 7242-7256 (2006).
47. Harrison JJ, Ceri H, Stremick CA, Turner RJ: Biofilm susceptibility to metal toxicity. Environ. Microbiol. 6, 1220-1227 (2004).
48. Yakandawala N, Gawande PV, Lovetri K, Madhyastha S: Effect of ovotransferrin, protamine sulfate and EDTA combination on biofilm formation by catheter-associated bacteria. J. Appl. Microbiol. 102, 722-727 (2007).
49. Toney JH, Koh ML: Inhibition of Xylella fastidiosa biofilm formation via metal chelators. JALA 11, 30-32 (2006).
50. Singh PK, Parsek MR, Greenberg EP, Welsh MJ: A component of innate immunity prevents bacterial biofilm development. Nature 417, 552-555 (2002).
51. Orsi N: The antimicrobial activity of lactoferrin: current status and perspectives. Biometals 17, 189-196 (2004).
52. Park RY, Sun HY, Choi MH, Bai YH, Chung YY, Shin SH: Proteases of a Bacillus subtilis clinical isolate facilitate swarming and siderophore-mediated iron uptake via proteolytic cleavage of transferrin. Biol. Pharm. Bull. 29, 850-853 (2006).
53. Kim SJ, Park RY, Kang SM, Choi MH, Kim CM, Shin SH: Pseudomonas aeruginosa alkaline protease can facilitate siderophore-mediated iron-uptake via the proteolytic cleavage of transferrins. Biol Pharm. Bull. 29, 2295-2300 (2006).
54. Zhang L-H, Dong Y-H: Quorum sensing and signal interference: diverse implications. Mol. Micro. 53, 1563-1571 (2004).
55. Smith RS, Iglewski BH: P aeruginosa quorum-sensing systems and virulence. Curr. Opin Microbiol. 6, 56-60 (2003).
56. Fuqua C, Parsek MR, Greenberg EP: Regulation of gene expression by cell-to-cell communication: acyl-homoserine lactone quorum sensing. Annu. Rev. Genet. 35, 439-468 (2001).
57. Rasmussen TB, Givskov, M: Quorum sensing inhibitors: a bargain of effects. Microbiology 152, 895-904 (2006).
58. Muh U, Schuster M, Heim R, Singh A, Olson ER, Greenberg EP: Novel Pseudomonas aeruginosa quorum-sensing inhibitors identified in an ultra-high-throughput screen. Antimicrob. Agents Chemother. 50, 3674-3679 (2006).
59. McDougald D, Rice SA, Kjelleberg S: Bacterial quorum sensing and interference by naturally occurring biomimics. Anal. Bioanal. Chem. 387, 445-453 (2007).
60. Gonzalez JE, Keshavan ND: Messing with bacterial gporurn sensing. Microbiol. Mol. Biol. Rev. 70, 859-875 (2006).
61. Bjamsholt T, Jensen PO, Rasmussen TB et al.: Garlic blocks quorum sensing and promotes rapid clearing of pulmonary Pseudomonas aeruginosa infections. Microbiology 151, 3873-3880 (2005).
62. Choo JH, Rukayadi Y, Hwang J-K: Inhibition of bacterial quorum sensing by vanilla extract. Lett. Appl. Microbiol. 42, 637-641 (2006).
63. Ren D, Zuo R, Gonzalez Barrios AF et al.: Differential gene expression for investigation of Escherichia coli biofilm inhibition by plant extract ursolic acid. Appl. Environ. Microbiol. 71, 4022-4034 (2005).
64. Hetrick EM, Schoenfisch MH: Reducing implant-related infections: active release stategies. Chem. Soc. Rev. 35, 780-789 (2006).
65. Stigter M, Bezemer J, de Groot K, Layrolle P: Incorporation of different antibiotics into carbonated hydroxyapatite coatings on titanium implants, release and antibiotic efficacy. J. Controlled Release 99, 127-137 (2004).
66. Schmidmaier G, Lucke M, Wildemann B, Haas NP, Rashke M: Prophylaxis and treatment of implant-related infections by antibiotic-coated implants: a review. Injury 37(Suppl. 2), S105-S112 (2006).
67. Nablo BJ, Prichard HL, Butler RD, Klitzman B, Schoenfisch MH: Inhibition of implant-associated infections via nitric oxide release. Biomaterials 26, 6984-6990 (2005).
68. Darouiche RO: Device-associated infections: a macroproblem that starts with microadherence. Clin. Infect. Dis. 33, 1567-1572 (2001).
69. Jones GL, Muller CT, O'Reilly M, Stickler DJ: Effect of triclosan on the development of bacterial biofilms by urinary tract pathogens on urinary catheters. J. Antimicrob. Chemother. 57, 266-272 (2006).
70. Laube N, Kleinen L, Bradenahl J, Meissner A: Diamond-like carbon coatings on ureteral stents - a new strategy for decreasing the formation of crystalline bacterial biofilms? J. Urol. 177, 1923-1927 (2007).
71. Valle J, Da Re S, Henry N et al.: Broad-spectrum biofilm inhibition by a secreted bacterial polysaccharide. Proc Natl Acad. Sci. USA 103, 12558-12563 (2006).
72. Stickler DJ, Morgan SD: Modulation of crystalline Proteus murabilis biofilm. development on urinary catheters. J. Med. Microbiol. 55, 489-494 (2006).
73. Lu TK, Collins JJ: Dispersing biofilms with engineered enzymatic bacteriophage. Proc. Natl Acad. Sci. USA 104, 11197-11202 (2007).